BioSpace News Archive

AmerisourceBergen Corporation reiterated its previously provided guidance for fiscal year 2022 and announced that its Board of Directors has authorized a new share repurchase program.

KalVista Pharmaceuticals, Inc. announced it will be presenting at the 13th Annual Jefferies Global Healthcare Conference on Wednesday, June 8, 2022 at 11:30 a.m. ET.

ProQR Therapeutics N.V. announced that its 2022 Annual General Meeting of Shareholders will take place on Thursday, June 30, 2022 at 14:00 CET via videoconference.

BioCryst Pharmaceuticals, Inc. announced that the company will present at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022, at 9:00 a.m. ET and the JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 15, 2022, at 12:00 p.m. ET.

ALX Oncology Holdings Inc. announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2022 Healthcare Conference on Wednesday, June 8 at 10:00 am ET in New York.

Kamada Ltd. announced that it will host a virtual analysts and investors meeting on Tuesday, June 7, 2022, at 12:00 PM Eastern Time to review its growth catalysts.

Atea Pharmaceuticals, Inc. announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a corporate overview and update at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 11:00 a.m. ET.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will present new preclinical data demonstrating that STAT3 degradation blocked Th17 development and cytokine release and prevented collagen-induced arthritis, a pre-clinical model of rheumatoid arthritis, at the EULAR 2022 Congress in Copenhagen, Denmark.

Rezolute, Inc., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, announced that Brian Roberts, M.D., previously Senior Vice President and Head of Clinical Development, has been promoted to Chief Medical Officer.

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, announced the appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer.